|
64 Companies |
|
21 Products |
|
21 Products |
|
23 Mechanisms of Action |
|
207 Trials |
|
10745 News |
|
| «12...125126127128129130131132133134135136137» |
- | iscalimab (CFZ533) / Novartis
New P2 trial: Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis (clinicaltrials.gov) - Oct 1, 2015
P2, N=44, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
New P3 trial: Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Sep 29, 2015
P3, N=10, Not yet recruiting, Sponsor: Catalyst Pharmaceuticals, Inc.
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=4, Terminated, Sponsor: St. Louis University
Trial primary completion date: Aug 2015 --> Dec 2015
- prednisone / Generic mfg.
Trial primary completion date: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (clinicaltrials.gov) - Sep 21, 2015
P3, N=126, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Nov 2015
- ||||| Soliris (eculizumab) / AstraZeneca
Enrollment closed: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (clinicaltrials.gov) - Sep 14, 2015
P3, N=92, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Trial primary completion date: Aug 2015 --> Nov 2015 Recruiting --> Active, not recruiting
- ||| Benlysta (belimumab) / GSK
Enrollment change: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Aug 17, 2015
P2, N=60, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting N=40 --> 60
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment change, Trial termination, Trial primary completion date: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=4, Terminated, Sponsor: St. Louis University
N=40 --> 60 N=10 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Aug 2015; Study stopped by sponsor due to difficulty enrolling at site
- |||| Clinical: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jul 29, 2015
P2, N=62, Recruiting, Sponsor: Grifols Therapeutics Inc.
N=10 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Aug 2015; Study stopped by sponsor due to difficulty enrolling at site Not yet recruiting --> Recruiting
- Trial primary completion date: A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations (clinicaltrials.gov) - Jul 16, 2015
P3, N=50, Recruiting, Sponsor: Grifols Therapeutics Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Jul 2016
- | Trial completion, Trial primary completion date: Therapeutic Plasma Exchange in MG (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=11, Completed, Sponsor: Duke University
Trial primary completion date: Sep 2015 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2014
- ||||| New P2 trial: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jun 17, 2015
P2, N=62, Not yet recruiting, Sponsor: Grifols Therapeutics Inc.
- ||||| New P2 trial: Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jun 17, 2015
P2, N=60, Recruiting, Sponsor: Grifols Therapeutics Inc.
- New trial: Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F (clinicaltrials.gov) - Jun 12, 2015
P=N/A, N=120, Completed, Sponsor: Assistance Publique - H
- | Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment open: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) - Apr 29, 2015
P2, N=25, Recruiting, Sponsor: Mazen Dimachkie, MD
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2014 Not yet recruiting --> Recruiting
- ||||||| tacrolimus oral / Generic mfg.
Trial completion: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis (clinicaltrials.gov) - Apr 27, 2015
P3, N=83, Completed, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial primary completion date: Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis (clinicaltrials.gov) - Apr 19, 2015
P1, N=10, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Feb 2017
- Trial termination: Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=100, Terminated, Sponsor: University of Texas
Trial primary completion date: Feb 2015 --> Feb 2017 Active, not recruiting --> Terminated
- ||| New P3 trial: A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations (clinicaltrials.gov) - Apr 10, 2015
P3, N=50, Recruiting, Sponsor: Grifols Therapeutics Inc.
- | Benlysta (belimumab) / GSK
Enrollment closed: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Mar 18, 2015
P2, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- | New P4 trial: The effect of tetanus revaccination in patients with myasthenia gravis Het effect of tetanus revaccinatie in patienten met myasthenia gravis. (EUDRACT) - Feb 20, 2015
P4, N=80, Ongoing, Sponsor: Leiden University Medical Center
- Enrollment closed: MAPLE: Study of an Intervention to Improve Problem List Accuracy and Use (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=140, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- || Trial primary completion date: QUESST: Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=200, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Mar 2015 --> Jun 2015
- | bortezomib / Generic mfg.
Enrollment open: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) - Dec 19, 2014
P2, N=18, Recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Mar 2015 --> Jun 2015 Not yet recruiting --> Recruiting
- | New P2 trial: The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor (clinicaltrials.gov) - Dec 16, 2014
P2, N=240, Recruiting, Sponsor: Tang-Du Hospital
- Trial primary completion date: Therapeutic Plasma Exchange in MG (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=10, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Jun 2015
- | Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial initiation date: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) - Dec 7, 2014
P2, N=25, Not yet recruiting, Sponsor: Mazen Dimachkie, MD
Trial primary completion date: Aug 2014 --> Jun 2015 Initiation date: Jun 2014 --> Jan 2015
- |||||||||| Soliris (eculizumab) / AstraZeneca
New P3 trial: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Nov 28, 2014
P3, N=92, Enrolling by invitation, Sponsor: Alexion Pharmaceuticals
- Enrollment open: MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=44, Recruiting, Sponsor: Assistance Publique - H
Initiation date: Jun 2014 --> Jan 2015 Not yet recruiting --> Recruiting
- | bortezomib / Generic mfg.
Trial initiation date: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) - Oct 17, 2014
P2, N=18, Not yet recruiting, Sponsor: Charite University, Berlin, Germany
Not yet recruiting --> Recruiting Initiation date: May 2014 --> Nov 2014
- Ventolin (albuterol) / GSK
Phase classification: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Oct 17, 2014
P1, N=21, Completed, Sponsor: Mayo Clinic
Initiation date: May 2014 --> Nov 2014 Phase classification: P=N/A --> P1
- Benlysta (belimumab) / GSK
Trial primary completion date: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Oct 2, 2014
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P=N/A --> P1 Trial primary completion date: Aug 2014 --> Aug 2015
- || Trial primary completion date: The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Dec 2013 --> Dec 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Sep 19, 2014
P2, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Jun 2014 --> Jun 2017
- | Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Enrollment closed, Trial primary completion date: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Aug 6, 2014
P3, N=36, Active, not recruiting, Sponsor: Catalyst Pharmaceutical Partners, Inc
Trial primary completion date: Jun 2014 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Sep 2014
- Trial initiation date: MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=44, Not yet recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Sep 2014 Initiation date: Feb 2014 --> Sep 2014
- Firdapse (amifampridine) / BioMarin, Catalyst Pharma
Clinical: EAP-001: Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS) (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=0, Available, Sponsor: Catalyst Pharmaceutical Partners, Inc
- | Enrollment closed: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) - Jul 4, 2014
P2, N=30, Active, not recruiting, Sponsor: Jacobus Pharmaceutical
Initiation date: Feb 2014 --> Sep 2014 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) - May 8, 2014
P2, N=50, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis (clinicaltrials.gov) - Apr 29, 2014
P1, N=10, Active, not recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Clinical: National Registry for Egyptian Pediatric Neuromuscular Diseases (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=200, Recruiting, Sponsor: Ain Shams University
- prednisone / Generic mfg., azathioprine / Generic mfg.
Enrollment closed: MYACOR: Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis (clinicaltrials.gov) - Apr 10, 2014
P4, N=114, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial: BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) - Apr 8, 2014
P2, N=50, Not yet recruiting, Sponsor: Yale University
- | Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Enrollment change: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Apr 1, 2014
P3, N=36, Recruiting, Sponsor: Catalyst Pharmaceutical Partners, Inc
Recruiting --> Active, not recruiting N=30 --> 36
- bortezomib / Generic mfg.
New P2 trial: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) - Apr 1, 2014
P2, N=18, Not yet recruiting, Sponsor: Charite University, Berlin, Germany
- | Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
New P2 trial: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) - Mar 30, 2014
P2, N=25, Not yet recruiting, Sponsor: Mazen Dimachkie, MD
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial: A Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) - Mar 19, 2014
P2, N=50, Not yet recruiting, Sponsor: Yale University
- |||||| Soliris (eculizumab) / AstraZeneca
Enrollment open: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (clinicaltrials.gov) - Mar 4, 2014
P3, N=92, Recruiting, Sponsor: Alexion Pharmaceuticals
N=30 --> 36 Not yet recruiting --> Recruiting
- Ventolin (albuterol) / GSK
Enrollment change: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=21, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting N=50 --> 21
- | Ventolin (albuterol) / GSK
Trial completion: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=21, Completed, Sponsor: Mayo Clinic
N=50 --> 21 Recruiting --> Completed
- ||||| tacrolimus oral / Generic mfg.
Enrollment closed: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis (clinicaltrials.gov) - Dec 9, 2013
P3, N=83, Active, not recruiting, Sponsor: Astellas Pharma Inc
Recruiting --> Completed Completed --> Active, not recruiting